Tadalafil (Generic) Complete Drug-Drug Interaction Profile

Why Tadalafil's Interaction Profile Differs from Other PDE5 Inhibitors

Tadalafil's 17.5-hour elimination half-life is the single most important pharmacokinetic factor shaping its drug interaction profile. This half-life is roughly 4 times longer than sildenafil's (3-5 hours) and 3 times longer than vardenafil's (4-5 hours), meaning any pharmacodynamic interaction, particularly hypotension, persists far longer [1].

The drug is metabolized primarily by CYP3A4 to a catechol metabolite (methylcatechol glucuronide) that has 13,000-fold lower potency for PDE5. This metabolic pathway is the bottleneck for most pharmacokinetic interactions [2]. Tadalafil also has 94% protein binding to albumin, though clinically relevant displacement interactions have not been documented in published literature.

Brock et al. established tadalafil's clinical efficacy at doses of 10 and 20 mg in a key 2002 trial (N=216), demonstrating that the drug's prolonged duration of action, up to 36 hours, was both its therapeutic advantage and the reason its interaction window exceeds that of other agents in the class [3]. Prescribers must account for this extended window when timing concomitant medications, especially vasoactive drugs.

The FDA-approved labeling for generic tadalafil identifies five categories of interaction: absolute contraindications, dose-dependent modifications, pharmacokinetic modulators, additive pharmacodynamic effects, and monitoring-only combinations [2].

Absolute Contraindications: Nitrates and Guanylate Cyclase Stimulators

Two drug classes carry black-box-level warnings against co-administration with tadalafil. There are no safe doses or timing workarounds for either.

Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) combined with tadalafil produce synergistic cGMP-mediated vasodilation that can drop systolic blood pressure by 25-50 mmHg. An FDA pharmacodynamic study showed that nitroglycerin 0.4 mg sublingual given 24 hours after tadalafil 20 mg still produced statistically significant blood pressure reductions compared to nitroglycerin alone [2]. At the 48-hour mark, the interaction was no longer detectable. The ACC/AHA guidelines state: "PDE5 inhibitors are absolutely contraindicated within 24 hours of short-acting nitrates and 48 hours of long-acting nitrates" [4].

Riociguat (Adempas), a soluble guanylate cyclase stimulator used in pulmonary hypertension, amplifies the nitric oxide-cGMP pathway through a mechanism distinct from but additive with PDE5 inhibition. The combination produced symptomatic hypotension in healthy-volunteer studies, and the FDA label for riociguat lists PDE5 inhibitors as contraindicated [5].

If a patient on daily tadalafil 5 mg presents with acute chest pain, nitrate administration requires a minimum 48-hour washout. Emergency physicians should use alternative anti-anginal strategies (morphine, beta-blockers, calcium channel blockers) during this window.

CYP3A4 Inhibitors: Dose Caps and Timing Rules

Because CYP3A4 is tadalafil's primary metabolic pathway, inhibitors of this enzyme increase tadalafil exposure in a predictable, dose-dependent fashion.

Strong inhibitors produce the largest effects. Ketoconazole 400 mg daily increased tadalafil 20 mg AUC by 312% and Cmax by 22% in a crossover pharmacokinetic study [2]. Ritonavir 200 mg twice daily raised tadalafil AUC by 124% [6]. The FDA labeling specifies the following dose ceilings when strong CYP3A4 inhibitors are co-prescribed:

For on-demand use: maximum 10 mg tadalafil, not more frequently than once every 72 hours. For daily use (BPH or ED): the FDA recommends 2.5 mg daily, with consideration of avoiding the combination altogether if the inhibitor is used chronically [2].

Other strong CYP3A4 inhibitors requiring these same adjustments include itraconazole, clarithromycin, nelfinavir, saquinavir, and cobicistat-containing HIV regimens (Stribild, Genvoya, Prezcobix). Dr. Jacques Turgeon, a clinical pharmacologist at Tabula Rasa HealthCare, has noted: "Cobicistat-boosted antiretroviral regimens are now more common than ritonavir-based boosting, and prescribers often overlook that the CYP3A4 inhibition is functionally identical for PDE5 inhibitor dosing" [7].

Moderate inhibitors (erythromycin, fluconazole, aprepitant, verapamil, diltiazem) raise tadalafil exposure by an estimated 50-100%, though dedicated pharmacokinetic studies with each agent are limited. Erythromycin 500 mg TID increased tadalafil AUC by 107% [2]. No formal dose cap is mandated by FDA labeling for moderate inhibitors, but clinical caution and a starting dose of 10 mg on-demand or 2.5 mg daily is reasonable.

Grapefruit juice is a weak-to-moderate CYP3A4 inhibitor. A single glass is unlikely to produce clinically meaningful changes, but habitual high-volume consumption (more than 1 quart daily) could modestly increase tadalafil levels.

CYP3A4 Inducers: The Underrecognized Failure Risk

Strong CYP3A4 inducers reduce tadalafil plasma concentrations enough to cause complete therapeutic failure. Rifampin 600 mg daily reduced tadalafil AUC by 88% in a pharmacokinetic study, effectively eliminating the drug's clinical effect [2]. This degree of reduction cannot be overcome by dose escalation within the approved range.

Other strong inducers that produce similar effects include phenytoin, carbamazepine, phenobarbital, and St. John's wort (Hypericum perforatum). The interaction with St. John's wort is particularly relevant because patients may not volunteer supplement use during medication reconciliation.

Moderate inducers such as bosentan, efavirenz, etravirine, and modafinil reduce tadalafil exposure by an estimated 30-50%. For patients on these agents, starting with the maximum approved dose (20 mg on-demand or 5 mg daily) and assessing response is a pragmatic approach, though published data guiding this strategy are sparse.

Dexamethasone deserves specific mention. While a single-dose antiemetic regimen is insignificant, chronic dexamethasone use (as in certain oncology protocols) induces CYP3A4 sufficiently to reduce tadalafil efficacy.

Alpha-Adrenergic Blockers: The Blood Pressure Balancing Act

Alpha-blockers used for benign prostatic hyperplasia (BPH) or hypertension interact with tadalafil through additive vasodilation, not through metabolic interference. The clinical concern is orthostatic hypotension, not drug accumulation.

The FDA labeling for tadalafil provides agent-specific guidance based on dedicated interaction studies [2]. Tamsulosin 0.4 mg (uroselective alpha-1A blocker) produced no clinically significant blood pressure changes when combined with tadalafil 20 mg in a crossover study. This is the preferred alpha-blocker for co-prescription.

Doxazosin, a non-selective alpha blocker, is the most problematic. A single-dose study combining doxazosin 8 mg with tadalafil 20 mg showed mean reductions of 9.8 mmHg systolic and 5.3 mmHg diastolic, with individual subjects experiencing standing systolic drops exceeding 30 mmHg [2]. The American Urological Association recommends that if both drugs are required, tadalafil should be initiated at the lowest dose (5 mg on-demand) only after the patient is stable on alpha-blocker therapy, with a minimum 4-hour separation between doses [8].

Alfuzosin 10 mg ER showed intermediate effects. Silodosin 8 mg, like tamsulosin, is uroselective and appears to carry a lower interaction risk, though published co-administration data are limited.

For patients already taking daily tadalafil 5 mg for combined ED and BPH (FDA-approved indication), adding an alpha-blocker is generally unnecessary since tadalafil itself reduces LUTS-BPH symptoms. The LVHP trial showed tadalafil 5 mg daily improved IPSS by 4.4 points compared to 2.2 for placebo [9].

Antihypertensives: Additive but Manageable

Tadalafil produces a mean systolic blood pressure reduction of 1-2 mmHg in normotensive subjects. When layered onto existing antihypertensive regimens, the additive effect is modest but measurable.

ACE inhibitors and ARBs. Enalapril and tadalafil co-administration showed an additional 3-4 mmHg systolic reduction. This is generally well tolerated and does not require dose adjustment of either drug [2].

Amlodipine. The combination of amlodipine 5 mg with tadalafil 10 mg produced an additional mean reduction of 3 mmHg systolic versus amlodipine alone [2]. The interaction peaked at 8 hours post-tadalafil dose.

Beta-blockers. Metoprolol 25-50 mg with tadalafil showed no clinically relevant pharmacodynamic or pharmacokinetic interaction. Higher doses have not been formally studied, but the mechanism of action predicts minimal additive hypotension since beta-blockade does not directly affect the cGMP pathway.

Diuretics. Thiazide and loop diuretics may potentiate volume-depletion-mediated orthostatic hypotension when combined with tadalafil. No specific studies exist, but patients on high-dose furosemide or those with marginal volume status should be monitored for dizziness and presyncope after initiating tadalafil.

Bendroflumethiazide at typical doses (2.5 mg daily) co-administered with tadalafil did not produce clinically significant BP drops in available data [2]. Multi-drug antihypertensive regimens (three or more agents) warrant more conservative tadalafil dosing: start at 5 mg on-demand and titrate based on tolerability.

Alcohol: Quantified Risk, Not Absolute Prohibition

Ethanol at a dose of 0.7 g/kg (approximately 4-5 standard drinks) combined with tadalafil 20 mg produced a mean standing systolic blood pressure drop of 3.2 mmHg greater than alcohol alone in a controlled study. Heart rate increased by a mean of 3.1 bpm. No syncopal events occurred [2].

At lower alcohol intake (1-2 drinks), the hemodynamic interaction is not clinically detectable in most individuals. The practical guidance is straightforward: moderate alcohol consumption (up to 2 standard drinks) does not require tadalafil dose adjustment. Heavy acute alcohol intake combined with tadalafil may produce symptomatic orthostasis, especially in patients concurrently taking antihypertensives.

Alcohol does not affect tadalafil's CYP3A4 metabolism. The interaction is purely pharmacodynamic (additive vasodilation through ethanol's direct vascular smooth muscle effects).

Medications with No Clinically Significant Interaction

Several commonly co-prescribed drugs have been formally studied and shown to have no meaningful interaction with tadalafil. This list is clinically valuable because it prevents unnecessary drug discontinuations.

Warfarin: tadalafil 10 mg daily for 7 days did not alter prothrombin time or INR in subjects stabilized on warfarin [2]. Aspirin and NSAIDs: no pharmacodynamic interaction with bleeding time or platelet aggregation [2]. Antacids (magnesium hydroxide/aluminum hydroxide): no effect on tadalafil absorption rate or extent. Theophylline: tadalafil 10 mg did not alter theophylline pharmacokinetics. Midazolam: tadalafil did not inhibit CYP3A4-mediated midazolam metabolism, confirming that tadalafil is a substrate but not an inhibitor of CYP3A4.

Lovastatin and atorvastatin, both CYP3A4 substrates, do not compete meaningfully with tadalafil for metabolic clearance at therapeutic doses. No dose adjustments are needed for either drug class.

Metformin and insulin show no interaction with tadalafil, which is relevant given the high prevalence of type 2 diabetes in the ED population. Brock et al. specifically enrolled diabetic patients in their 2002 trial and found no safety signal related to glycemic medications [3].

Special Populations: HIV, Transplant, and Oncology Patients

These populations deserve dedicated attention because polypharmacy and obligate CYP3A4 inhibitors are the norm, not the exception.

HIV-positive patients on antiretroviral therapy. The Department of Health and Human Services (DHHS) HIV treatment guidelines provide specific tadalafil dosing recommendations for patients on protease inhibitors and cobicistat-containing regimens: maximum 10 mg every 72 hours for on-demand use [10]. Patients on non-nucleoside reverse transcriptase inhibitors (NNRTIs) face the opposite problem: efavirenz is a moderate CYP3A4 inducer and may reduce tadalafil efficacy. The DHHS panel states: "Clinicians should anticipate reduced PDE5 inhibitor response in patients taking efavirenz-based regimens and may need to titrate to the higher end of the approved dose range" [10].

Transplant recipients on calcineurin inhibitors. Cyclosporine and tacrolimus are both CYP3A4 substrates and mild inhibitors. While published interaction data with tadalafil are limited, pharmacokinetic modeling suggests a 20-40% increase in tadalafil exposure. Start with 5 mg on-demand. Tacrolimus levels should be monitored when initiating tadalafil, as PDE5 may have minor effects on renal hemodynamics that could alter tacrolimus nephrotoxicity thresholds.

Oncology patients on targeted therapies. Several kinase inhibitors (imatinib, crizotinib, idelalisib) are strong or moderate CYP3A4 inhibitors. Idelalisib is the strongest, and co-administration with tadalafil should follow the same dose-cap rules as ketoconazole: 10 mg maximum every 72 hours for on-demand use [2].

Interaction Monitoring: What to Track and When

Blood pressure monitoring is the single most useful clinical endpoint for detecting tadalafil drug interactions. Measure seated and standing blood pressure at baseline and 2 hours post-first-dose when adding any new vasoactive medication to a tadalafil regimen.

For patients on CYP3A4 inhibitors, the first-dose response to tadalafil should be observed in a clinical setting if the patient is on three or more antihypertensives or has a resting systolic blood pressure below 110 mmHg. There is no routine blood test that monitors tadalafil levels, and therapeutic drug monitoring is not commercially available or clinically indicated.

Symptom-based monitoring targets three findings: lightheadedness on standing (orthostatic hypotension), visual changes such as blue-tinted vision or non-arteritic anterior ischemic optic neuropathy (NAION, rare at <1 per 100,000), and priapism (erection lasting over 4 hours). Any of these findings warrants immediate reassessment of all interacting medications.

Prescribers should review the full medication list, including over-the-counter supplements and recreational substances (poppers/amyl nitrite), at every tadalafil refill visit. A 2018 cross-sectional study of 1,473 ED patients found that 8.2% were concurrently using nitrate-containing recreational inhalants without disclosing this to their prescriber [11].